Yehia I. Mohamed

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Ahmed O. Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 241 citations · Full text

Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells

Li Gu, Yahui Zhu, Maiya Lee et al. · Proceedings of the National Academy of Sciences · 2023 · 41 citations · Full text

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

Thomas Talbot, Antonio D’Alessio, Matthias Pinter et al. · Liver International · 2022 · 34 citations · Full text

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Ahmed O. Kaseb, Hop Sanderson Tran Cao, Yehia I. Mohamed et al. · Journal of Clinical Oncology · 2020 · 27 citations

Surgical Oncology, Pathologic Complete Response, Clinical Endpoint +23

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Sirish Dharmapuri, Umut Özbek, Hiren Jethra et al. · World Journal of Gastrointestinal Oncology · 2023 · 20 citations · Full text